November 30, 2021 -- Ranok Therapeutics and Pfizer are teaming up to evaluate Ranok's chaperone-mediated protein degradation (CHAMP) platform technology on an undisclosed cancer target.
CHAMP takes advantage of the cellular chaperone network, which could potentially improve the technology's safety and efficacy due to the selective targeting of tumors versus other targeted protein degradation approaches, Ranok said.
Ranok received $40 million in series B financing in August 2021.
Financial details of the agreement were not disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
